179689-21-5

Basic information

• Product Name: Ethyl 2-chloro-5-nitronicotinate
• Synonyms: 1-Piperidinecarboxylic acid, 4-(2-methoxy-2-oxoethoxy)-, 1,1-dimethylethyl ester
• CAS NO: 179689-21-5
• Molecular Formula: C8H7ClN2O4
• Molecular Weight: 231
• Mol File: 179689-21-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl 2-chloro-5-nitronicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-chloro-5-nitronicotinate(179689-21-5)
• EPA Substance Registry System: Ethyl 2-chloro-5-nitronicotinate(179689-21-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 179689-21-5(Hazardous Substances Data)

Usage

General Description

Ethyl 2-chloro-5-nitronicotinate is a chemical compound with the molecular formula C8H6ClNO4. It is a nitro-substituted nicotinate derivative that is commonly used in organic synthesis and pharmaceutical research. Ethyl 2-chloro-5-nitronicotinate is characterized by the presence of a chlorine atom and a nitro group attached to a nicotinic acid ester. It is used as a building block in the synthesis of various biologically active compounds and pharmaceutical intermediates due to its versatile reactivity and functional group tolerance. Additionally, it has potential applications in the development of herbicides and pesticides. The compound is considered to be moderately hazardous, and appropriate safety measures should be taken when handling it.

Upstream product

• 96-32-2 bromoacetic acid methyl ester 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 146117-95-5 methyl 4-piperidinyloxy-acetate hydrochloride 
• 163210-40-0 tert-butyl 4-(2-hydroxyethoxy)piperidine-1-carboxylate 

Relevant articles and documents

Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands

With the aim to obtain potent adenosine A2A receptor (A2AR) ligands, a series of eighteen derivatives of 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide (SYN-115, Tozadenant) were designed and synthesized. The target compounds were obtained by a chemical building block principle that involved reaction of the appropriate aminobenzothiazole phenyl carbamates with either commercially available or readily synthesized functionalized piperidines. Their affinity and subtype selectivity with regard to human adenosine A1-and A2A receptors were determined using radioligand binding assays. Ki values for human A2AR ranged from 2.4 to 38 nM, with more than 120-fold selectivity over A1 receptors for all evaluated compounds except 13k which had a Ki of 361 nM and 18-fold selectivity. The most potent fluorine-containing derivatives 13e, 13g and 13l exhibited Ki values of 4.9 nM, 3.6 nM and 2.8 nM for the human A2AR. Interestingly, the corresponding values for rat A2AR were found to be four to five times higher. Their binding to A2AR was further confirmed by radiolabeling with 18F and in vitro autoradiography in rat brain slices, which showed almost exclusive striatal binding and complete displacement by the A2AR antagonist ZM 241385. We conclude that these compounds represent potential candidates for the visualization of the A2A receptor and open pathways to novel therapeutic treatments of neurodegenerative disorders or cancer.

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS

Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for

Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Piperazine derivatives useful in the treatment or prevention of inflammation, bone degradation, thrombosis and tumor metastasis. Exemplary species are: (a) ?4-trans-?3-?4-(4-Pyridyl)-piperazin-1-yl!propionyl!amino!-cyclohexanecarboxylic acid, (b) 3-?4-trans-?4-(4-Pyridyl)-piperazin-1-yl!carbonylamino!-cyclohexylpropionic acid, (c) 3-?4-trans-?4-(4-Pyridyl)-piperazin-1-yl!malonylamino!cyclohexylcarboxylic acid, (d) Methyl ?4-trans-?3-?4-(4-pyridyl)-piperazin-1-yl!-propionyl!-amino!cyclohexane carboxylate, (e) Methyl 3-?4-trans-?4-(4-pyridyl)-piperazin-1-yl!-carbonylamino!cyclohexyl propionate, (f) Methyl ?4-trans-?4-(4-pyridyl)-piperazin-1-yl!-malonylamino!-cyclohexyl carboxylate, (g) Cyclohexyl ?4-trans-??4-(4-pyridyl)-piperazin-1-yl!-acetyl!-amino!-cyclohexane carboxylate, and (h) Isobutyl ?4-trans-??4-(4-pyridyl)-piperazin-1-yl!-acetyl!-amino!-cyclohexane carboxylate.